Amrize (NYSE:AMRZ) vs. PT Semen Indonesia (Persero) Tbk (OTCMKTS:PSGTY) Financial Survey

Amrize (NYSE:AMRZ) and PT Semen Indonesia (Persero) Tbk (OTCMKTS:PSGTY) are both basic materials companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares Amrize and PT Semen Indonesia (Persero) Tbk’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amrize	N/A	N/A	N/A
PT Semen Indonesia (Persero) Tbk	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Amrize and PT Semen Indonesia (Persero) Tbk, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amrize	0	7	7	1	2.60
PT Semen Indonesia (Persero) Tbk	0	0	0	0	0.00

Amrize currently has a consensus price target of $60.00, indicating a potential upside of 7.43%. Given Amrize’s stronger consensus rating and higher probable upside, analysts clearly believe Amrize is more favorable than PT Semen Indonesia (Persero) Tbk.

Earnings and Valuation

This table compares Amrize and PT Semen Indonesia (Persero) Tbk”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amrize	$11.70 billion	2.64	$1.27 billion	$1.84	30.35
PT Semen Indonesia (Persero) Tbk	N/A	N/A	N/A	$18,720.72	0.00

Amrize has higher revenue and earnings than PT Semen Indonesia (Persero) Tbk. PT Semen Indonesia (Persero) Tbk is trading at a lower price-to-earnings ratio than Amrize, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

0.0% of PT Semen Indonesia (Persero) Tbk shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Amrize beats PT Semen Indonesia (Persero) Tbk on 6 of the 8 factors compared between the two stocks.

About Amrize

Amrize AG focuses on building materials business in North America. The company was incorporated in 2023 and is based in Zug, Switzerland. Amrize AG operates independently of Holcim AG as of June 23, 2025.

About PT Semen Indonesia (Persero) Tbk

PT Semen Indonesia (Persero) Tbk manufactures, packs, and distributes cement in Indonesia and internationally. It operates through Cement Production and Non-Cement Production segments. The company is also involved in limestone and clay mining; cement bag manufacturing; industrial real estate development and building rental; ready-mix concrete and aggregates quarry production; and consulting, mining, trading, transportation, and construction activities. In addition, it engages in the information system, investment, freight forwarding, stevedoring, sea transportation, service logistic management, outsourcing, and building materials businesses, as well as procures public goods and services. The company was formerly known as PT Semen Gresik (Persero) Tbk and changed its name to PT Semen Indonesia (Persero) Tbk in January 2013. PT Semen Indonesia (Persero) Tbk was founded in 1953 and is headquartered in Jakarta Selatan, Indonesia.